NeXstar Moves From Start-Up To Swallowed-Up: Gilead Is Buyer
Gilead's approximately $500 mil. stock acquisition of NeXstar will bring Gilead $55 mil. in cash, a $100 mil. revenue stream and an international sales organization.
You may also be interested in...
The topoisomerase I inhibitor NX211 is the most advanced drug candidate OSI Pharmaceuticals will add through its acquisition of Gilead's oncology research program
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011